Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 16, 2026 is 275.52 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 284.19 % — a change of -3.05% (lower).

Cash Conversion

275.52 %

YoY

-3.05%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp is 2025 275.52 % . Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp was 2024 284.19 % . It decreases by -3.05% lower compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
219.54 CNY
Jan 1, 2019
485.95 CNY
Jan 1, 2020
-192.61 CNY
Jan 1, 2021
206.64 CNY
Jan 1, 2022
231.79 CNY
Jan 1, 2023
280.89 CNY
Jan 1, 2024
284.19 CNY
Jan 1, 2025
275.52 CNY
The Vcanbio Cell & Gene Engineering Corp Cash Conversion history
YEARCash ConversionYoY
275.52 %-3.05%
284.19 %+1.17%
280.89 %+21.18%
231.79 %+12.17%
206.64 %-207.28%
-192.61 %-139.64%
485.95 %+121.35%
219.54 %-67.61%
677.85 %+78.63%
379.47 %+9,571.50%
3.92 %-99.37%
624.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp Ltd is a biotechnology company based in Tianjin, China, operating within the healthcare sector. The company has been publicly traded since its IPO on May 4, 1993, and is listed under the ticker 600645.SS with ISIN CNE000000545. It employs 2,332 full-time staff and focuses on the development of life sciences technology. Vcanbio engages in cell culture, gene detection, and storage services, as well as the production and sale of cytokines culture solutions, cosmetics, and detection reagents. The company primarily serves domestic markets in China, with its headquarters located in Tianjin. Its website is http://www.vcanbio.com. The firm's business activities include the development and application of biotechnology solutions, though specific details on product names, acquisitions, or additional financial figures are not provided in the available information. Vcanbio operates as a public company with a presence in the Chinese biotechnology industry, emphasizing innovation in cell and gene engineering. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp is 275.52 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp changed from 284.19 % to 275.52 %, representing a -3.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vcanbio Cell & Gene Engineering Corp

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vcanbio Cell & Gene Engineering Corp